Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.66 |
| ▸ | TERT | O14746 | 2/20 | 0.60 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.51 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.51 |
| ▸ | ITGAL | P20701 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789440 | 0.83 | HDAC1 (0.79) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL14818784 | 0.82 | HDAC3 (0.62) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL11719473 | 0.81 | HDAC3 (0.72) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL7273295 | 0.81 | HDAC1 (0.66) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL15966086 | 0.81 | HDAC3 (0.63) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| Hydrochloric Acid SCHEMBL8957362 | 0.80 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL8241153 | 0.80 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL28994432 | 0.79 | TERT (0.48) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL27736940 | 0.79 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL25248640 | 0.79 | HDAC3 (0.72) | HDAC3HDAC1HDAC2HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2953457-A2 | ERK INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | HDAC3 770/4885HDAC1 789/4885HDAC2 976/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | HDAC3 1673/4885HDAC1 931/4885HDAC2 1219/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | HDAC3 770/4885HDAC1 789/4885HDAC2 976/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | HDAC3 770/4885HDAC1 789/4885HDAC2 976/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | HDAC3 770/4885HDAC1 789/4885HDAC2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.